Breast Cancer | Specialty

Introduction: Impact of Molecular Subtyping in Breast Cancer

February 25th 2015

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

February 24th 2015

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Swain Discusses Final Survival Analysis of CLEOPATRA Study

February 24th 2015

For additional insight on the CLEOPATRA trial and its implications for clinical practice, OncLive interviewed Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center.

Unprecedented OS Benefit Cements Pertuzumab Regimen as Frontline Standard in HER2-Positive MBC

February 20th 2015

Frontline pertuzumab plus trastuzumab and docetaxel improved survival by nearly 16 months in metastatic HER2-positive breast cancer, according to results from the phase III CLEOPATRA study that are now published in The New England Journal of Medicine.

Slamon's Tenacity Advances the Field of Breast Cancer Research

February 19th 2015

Dennis J. Slamon, MD, PhD, has had an immeasurable impact on the treatment of women with breast cancer by developing trastuzumab (Herceptin) and helping to launch the era of targeted therapies. He was honored in the Breast Cancer category with a 2014 Giants of Cancer Careâ„¢ award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

Chemobrain-It's Real, It's Complex, and the Science Is Still Evolving

February 17th 2015

Talk with almost any cancer survivor, and she/he is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory.

Lung Cancer Screening, Trabectedin in Soft Tissue Sarcoma, and More

February 12th 2015

Palbociclib: An Exciting New Option in Breast Cancer

February 12th 2015

Integrating Palbociclib Into the Treatment of Breast Cancer

February 12th 2015

Preclinical and Clinical Evidence Supporting Palbociclib

February 12th 2015

SABCS Studies Highlight Promise and Complexity in Targeting PI3K in Breast Cancer

February 9th 2015

Although there is a significant scientific rationale for targeting the PI3K pathway in breast cancer, research findings presented recently at the 2014 San Antonio Breast Cancer Symposium (SABCS) highlight the inherent complexities in using agents directed at this cell-signaling network.

Latest News & Insight: February 5, 2015

February 6th 2015

Dr. Shih on Treating Lobular vs Ductal Breast Cancers

February 5th 2015

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

Dr. Lori Goldstein on Neoadjuvant Treatment for HER2+ Breast Cancer

February 4th 2015

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.

Dr. Germain on Scientific Rationale Behind Bortezomib/Fulvestrant for HR+ Breast Cancer

February 3rd 2015

Doris Germain, PhD, ‎associate professor at Mount Sinai Cancer Institute, discusses the scientific rationale behind a clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.

FDA Approves Palbociclib for Metastatic Breast Cancer

February 3rd 2015

The FDA has granted an accelerated approval to palbociclib as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

Dr. Denise Yardley on PI3K Inhibitors

January 29th 2015

Denise Yardley, MD, senior investigator, breast cancer research, Sarah Cannon Research Institute discusses the phase II FERGI study and how it can be applied to more than just breast cancer.

Dr. David Rimm on Immunofluorescence for HER2 Identification

January 26th 2015

David Rimm MD, PhD, professor of pathology and medicine, director of pathology tissue services, Yale University School of Medicine, explains the benefits of quantitativecfor the measurement of HER2 proteins.

Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast Cancer

January 23rd 2015

Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference.

Latest News & Insight: January 23, 2015

January 23rd 2015